It's a spherical world, after all.
NYS Entity Status
NYS Filing Date
JUNE 13, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - FIESTA FUSION INC.
AROUND THE WEB
- Hands-On With GoPro's New Fusion 360 Camera
By Brent Rose - Tuesday Jun 13, 2017
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- Beer and...Iced Tea?
Friday Apr 21, 2017
Looking for a refreshing drink this summer? WSJ reporter Charles Passy and Tanya Rivero sip an unconventional option: the Owl's Brew Radler, a new artisanal beer and iced tea fusion. Photo: Owl's Brew
- Sketchy firm behind Trump dossier is stalling investigators
By Paul Sperry - Saturday Jun 24, 2017
A secretive Washington firm that commissioned the dubious intelligence dossier on Donald Trump is stonewalling congressional investigators trying to learn more about its connections to the Democratic Party. The Senate Judiciary Committee earlier this month threatened to subpoena the firm, Fusion GPS, after it refused to answer questions and provide records to the panel identifying...
- Soupman Inc. of 'Seinfeld' Fame Seeks Bankruptcy Protection
Tuesday Jun 13, 2017
Soupman Inc., of “Seinfeld” fame, filed for bankruptcy protection Tuesday, just weeks after a top company executive was charged with tax evasion.
- A Slump in Tech Stocks That Leaves Some Investors Mystified
By LANDON THOMAS Jr. - Monday Jun 12, 2017
Shares of Netflix, Apple and other giant technology companies that have powered a market rally have taken an uncharacteristic pause.
- Ask the NY Giants: Socks with Sandals?
Tuesday Sep 15, 2015
Professional athletes like members of the New York Giants are the inspiration for the latest (counterintuitive) high-fashion trend: wearing socks with sandals. Photo: Stu Woo/The Wall Street Journal
- Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?
By Ben Fidler - Saturday Jun 3, 2017
When the FDA last week approved Merck’s cancer drug pembrolizuamb (Keytruda) for tumors with a specific genetic signature, regardless of what body part they originated in, it was a watershed moment for oncology and a victory for the concept of precision medicine. But Merck isn’t alone; others are following suit with similar plans, and their […]